Adjuvanted RSVPreF3 vaccine clinical trials

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

This study looks at how long an RSV vaccine protects adults aged 18 and over who have had a lung or kidney transplant. It also checks how safe the vaccine is and how well it boosts protection when they get another dose.